Wedge Capital Management L L P NC Grows Stake in Pfizer Inc. $PFE

Wedge Capital Management L L P NC boosted its holdings in shares of Pfizer Inc. (NYSE:PFE) by 8.0% during the 4th quarter, Holdings Channel reports. The firm owned 1,141,163 shares of the biopharmaceutical company’s stock after buying an additional 84,924 shares during the period. Wedge Capital Management L L P NC’s holdings in Pfizer were worth $28,415,000 at the end of the most recent reporting period.

Other large investors also recently added to or reduced their stakes in the company. Flywheel Private Wealth LLC purchased a new position in Pfizer during the fourth quarter valued at $337,000. KMG Fiduciary Partners LLC lifted its stake in Pfizer by 7.5% in the 4th quarter. KMG Fiduciary Partners LLC now owns 142,189 shares of the biopharmaceutical company’s stock worth $3,541,000 after purchasing an additional 9,941 shares in the last quarter. Accurate Wealth Management LLC boosted its holdings in shares of Pfizer by 8.3% during the 4th quarter. Accurate Wealth Management LLC now owns 44,748 shares of the biopharmaceutical company’s stock valued at $1,140,000 after purchasing an additional 3,437 shares during the last quarter. Net Worth Advisory Group purchased a new position in shares of Pfizer during the fourth quarter valued at about $830,000. Finally, Dakota Wealth Management grew its position in shares of Pfizer by 4.8% during the fourth quarter. Dakota Wealth Management now owns 364,954 shares of the biopharmaceutical company’s stock valued at $9,087,000 after purchasing an additional 16,568 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting Pfizer

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Late‑stage clinical wins broaden Pfizer’s pipeline beyond COVID — a partnered 6‑valent Lyme vaccine showed ~75% Phase 3 efficacy and several oncology/immunology programs met key endpoints, supporting a re‑rating of growth prospects. Should Pfizer’s (PFE) New Lyme Vaccine and Oncology Wins Reshape Its Post‑COVID Pipeline Story?
• Positive Sentiment: Guggenheim raised its price target and reiterated a Buy, citing favorable risk/reward ahead of Phase 3 MEVPRO‑1 data — that analyst support can underpin short‑term investor interest. Guggenheim Sees Favorable Risk-Reward for Pfizer (PFE) Ahead of Phase 3 Data
• Positive Sentiment: Multiple bullish notes and “strong buy” theses are circulating after recent trial/portfolio progress, which can attract income and value investors looking for upside plus yield. Why Pfizer Remains A Strong Buy In 2026
• Neutral Sentiment: Jim Cramer mentioned PFE but said he needs more clarity on product flow — a reminder that mainstream TV coverage can move short‑term flows but hasn’t changed fundamentals. Jim Cramer on Pfizer: “I Just Need to Know Their Product Flow Better”
• Neutral Sentiment: Citi and other outlets continue to rate PFE around Hold/Neutral — signaling mixed analyst conviction despite select upgrades. Citi Remains a Hold on Pfizer (PFE)
• Negative Sentiment: A bearish view argues Wall Street overestimates PFE’s target price, pointing to political threats (e.g., “TrumpRx”, most‑favored‑nation pricing) that could compress margins and support a multi‑year earnings downside. That policy risk is pressuring valuation. Pfizer: Why Wall Street Habitually Overestimates Target Price
• Negative Sentiment: Income‑focused coverage flags payout safety concerns: Pfizer’s high yield draws attention but raises questions about sustainability if earnings weaken, which can amplify downside for dividend investors. Income Investors Face a Hard Truth About Pfizer’s Payout Safety

Analyst Ratings Changes

A number of research firms recently commented on PFE. Morgan Stanley set a $27.00 target price on Pfizer and gave the stock a “positive” rating in a research report on Tuesday, March 17th. UBS Group began coverage on Pfizer in a research note on Tuesday, January 6th. They issued a “neutral” rating and a $25.00 price objective on the stock. HSBC upped their price objective on Pfizer from $29.00 to $32.00 and gave the stock a “buy” rating in a report on Tuesday, March 17th. Citigroup assumed coverage on Pfizer in a research report on Tuesday, December 2nd. They set a “neutral” rating and a $26.00 target price for the company. Finally, Argus upgraded shares of Pfizer from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Monday, March 2nd. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have given a Hold rating and three have given a Sell rating to the stock. According to MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.19.

Pfizer Trading Down 2.0%

Shares of NYSE PFE opened at $27.03 on Friday. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The business’s 50 day moving average is $26.84 and its two-hundred day moving average is $25.68. The stock has a market capitalization of $153.70 billion, a P/E ratio of 19.88 and a beta of 0.47.

Pfizer (NYSE:PFE) last posted its quarterly earnings data on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.57 by $0.09. The business had revenue of $17.56 billion during the quarter, compared to analyst estimates of $16.93 billion. Pfizer had a return on equity of 20.48% and a net margin of 12.42%.The company’s revenue for the quarter was down 1.2% on a year-over-year basis. During the same period last year, the company earned $0.63 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current year.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.